Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guangan He

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Journal of the National Cancer Institute|August 5, 2011
The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cellsXiao-Feng Le, Weiqun Mao, Guangan He, et al.
Molecular Pharmaceutics|October 29, 2025
Profiling the Preclinical Pharmacokinetics and Biodistribution of a Platinum(IV)-Based Oxaliplatin Prodrug OxaliTEX and Their Significance to Antitumor ResponseGuangan He, Gregory D Thiabaud, Kathryn A Shelton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2012
Tissue platinum concentration and tumor response in non-small-cell lung cancerEric S Kim, J Jack Lee, Guangan He, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2020
Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor ImmunityBangxing Hong, Valerie Chapa, Uksha Saini, et al.
Cancers|March 14, 2026
MicroRNA-625-3p Increases Chemosensitivity in Ovarian Cancer Cells Through Decreasing SSX2IP-Mediated Cisplatin Export in Extracellular VesiclesChi-Lam Au-Yeung, Tetsushi Tsuruga, Marina A Talor, et al.
Clinical Epigenetics|March 26, 2015
Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapyApostolia M Tsimberidou, Rabih Said, Kirk Culotta, et al.
Ebiomedicine|January 19, 2019
PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axisCristian Rodriguez-Aguayo, Emine Bayraktar, Cristina Ivan, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 18, 2020
Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agentsGrégory Thiabaud, Guangan He, Sajal Sen, et al.
Neoplasia (New York, N.Y.)|May 2, 2013
Biologic effects of dopamine on tumor vasculature in ovarian carcinomaMyrthala Moreno-Smith, Sun Joo Lee, Chunhua Lu, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Journal of the National Cancer Institute|August 5, 2011
The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cellsXiao-Feng Le, Weiqun Mao, Guangan He, et al.
Molecular Pharmaceutics|October 29, 2025
Profiling the Preclinical Pharmacokinetics and Biodistribution of a Platinum(IV)-Based Oxaliplatin Prodrug OxaliTEX and Their Significance to Antitumor ResponseGuangan He, Gregory D Thiabaud, Kathryn A Shelton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2012
Tissue platinum concentration and tumor response in non-small-cell lung cancerEric S Kim, J Jack Lee, Guangan He, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2020
Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor ImmunityBangxing Hong, Valerie Chapa, Uksha Saini, et al.
Cancers|March 14, 2026
MicroRNA-625-3p Increases Chemosensitivity in Ovarian Cancer Cells Through Decreasing SSX2IP-Mediated Cisplatin Export in Extracellular VesiclesChi-Lam Au-Yeung, Tetsushi Tsuruga, Marina A Talor, et al.
Clinical Epigenetics|March 26, 2015
Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapyApostolia M Tsimberidou, Rabih Said, Kirk Culotta, et al.
Ebiomedicine|January 19, 2019
PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axisCristian Rodriguez-Aguayo, Emine Bayraktar, Cristina Ivan, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 18, 2020
Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agentsGrégory Thiabaud, Guangan He, Sajal Sen, et al.
Neoplasia (New York, N.Y.)|May 2, 2013
Biologic effects of dopamine on tumor vasculature in ovarian carcinomaMyrthala Moreno-Smith, Sun Joo Lee, Chunhua Lu, et al.
Pageof 2